

A Review of Candidate Therapies for Beta Coronavirus a Molecular Research

Fatema Bassam Ahmed

Aili Lyu

Coronavirus disease 2019 (COVID-19) is an infectious illness caused by the coronavirus 2 that causes severe acute respiratory illness (SARS-CoV-2). The first instance of this virus was reported on November 17th, 2019 in Wuhan, China. The COVID-19 outbreak is evidenced with devastating consequences such as 34.9% rate of mortality in 27 countries. The metastasizing of COVID-19 all over the world is alarmed to cause significant losses of human life, and for this there is no specific vaccination or therapy for COVID-19 in particular. The therapies suggested at this time are adapted from the treatments of Severe Acute Respiratory Syndrome (SARV-CoV). For instance, the development for a particular therapy or vaccination for COVID-19 is an urgent requirement. The pattern of study is based on investigating the research papers for the period of 2012-2020, identifying all the potential aspects of medical research contributing for the development of treatment against diverse families of coronavirus. By analyzing this approach, this study is aimed to provide a directed approach for developing appropriate therapy for COVID-19.

Introduction

The molecular structure of coronavirus is an RNA virus incorporating about 27-32 KB positive-sense-single-stranded RNA [1]. The family origin of coronavirus is linked to Coronaviridae family that includes coronavirus diversification as alpha, beta, delta and gamma [2, 3]. Classification of COVID-19 with respect to diversity of coronavirus origin was studied and investigated by taking sputum samples of oropharyngeal and nasopharyngeal swab, followed by real-time RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction), virus isolation, construction of next generation sequencing (NGS) library of viral genome with full-length, followed by sequencing analysis and finally examined with transmission electron microscopy identified that new coronavirus SARS-CoV-2 (identified from COVID-19 disease, evidenced in Wuhan, China) as betacoronavirus [1]. Moreover, the investigations for identifying the similarities and differences of SARS-CoV-2 with SARS-CoV and MERS-CoV, it was found with not extreme differences with respect to demographic characteristics, radiological and laboratory findings for MERS-CoV and SARS-CoV [4]. Therefore this paper examines the various approaches for treatment of SARS-CoV and MERS-CoV predicting a directive approach for developing COVID-19 vaccination.

Methods

This research is designed by carrying out thorough investigation of the previous researches for the period of 2012-2020, identifying the pathogenic investigation for coronavirus, and the analysis of antiviral treatments developed for coronavirus treatment during 2012 and 2015 coronavirus outbreak. For investigating the origin of SARS-CoV-2, the previous studies found the origin for MERS and SARS were evaluated.

Collected Data and its Analysis

Origin of Coronavirus

MERS-CoV is enlisted in the zoonotic category found with origin from animals determining the main cause of its spread from physical contact with an infected animal [5, 6]. In general, MERS-CoV was identified with its origin to dromedary camels [7], yet some other investigations found that genome of this virus is identified with its origin in bats that is suspected to be transmitted from bats (animal reservoir) to camels (intermediate host) [5, 8]. The first identification of this virus was found in 2002 (identified as SARS), having its origin from bats (animal reservoir) and then to palm civets (as intermediate hosts) [4]. Then it was observed in 2012 in Saudi Arabia and in 2015 in Korea, and in the current time in 2019, in Wuhan [4]. For instance, SARS-CoV-2 is similar to MERS-CoV and SARS-CoV for demographical aspects and originating from bats, yet the intermediate host is still unknown [4].

Transmission Mode

The transmission mode for MERS-CoV was reported mainly with human-to-human interaction [8-10]. Moreover another study reported that 83% of the transmissions were observed with human-to-human contact, whereas 44% of cases were spread with nosocomial transmission [11], and the secondary mode (household contacts) of transmission is 4% [12]. For SARS-CoV-2 the investigations have identified a greater prevalence of virus replication, and hence causing considerably higher rate of its spread as compared to MERS-CoV and SARS-CoV [4].

Causes of Infection

Investigations identified that obesity, diabetes, cardiac malfunctioning, immune-compromised state, pulmonary disease as the risk factors of coronavirus [13, 14]. Also, the asymptomatic healthcare workers are observed with viral shedding at a delayed pace taking about 5 weeks, where not wearing masks or gloves potentially increases the chances of viral infection in the healthcare workers [15]. Moreover the people lying under old age group, and conditions involving comorbid situation are vulnerable to cause higher rate of coronavirus infection [16]. Also, diabetes mellitus (DM) and MERS-CoV were observed with a possible relationship as in 2012 outbreak, DM patients were found at increased risk for MERS-CoV severity [17-21] - whereas 2015 outbreak showed that coronavirus patients having lesser rate of DM, hence identifying an unclear relationship of DM with coronavirus infection [22-24].

Analyzing Experimental Cases for Therapies and Vaccination

A research examined the severity level of MERS-CoV, by selecting 17 patients during 2015 Korea outbreak - there was the use of enzyme-linked immunosorbent assay for measuring levels of cytokine and chemokine serum by analyzing serial serums' samples [23]. The period of 18 days was the effervescence median time, indicating severe cases with extreme infiltrates of chest within one week of infection, and dyspnea was observed as soon as the first week of infection ended, gradually indicating visible symbols as second week of infection is started [23]. The group of patients with severe illness was found with with higher level as, whereas the and (serum levels) were observed with increment in the second week, such as versus and versus. This experiment implemented IFN- α , and found no impact on the mild cases [23]. On the other hand, another study indentified the severity of disease by chest radiography [25]. Such as the diagram shows severe infection (A), and infection at mild level (B): (Figure 1).

Figure 1. Chest Radiograph [25].

Another study identified the therapy with combining ribavirin and IFN- α 2a is observed with increasing the survival expectancy of severe cases (versus) [26]. Another study examined the deficiency of IFN- β 1a, is expected to increase the severity of MERS-CoV infection, whereas ribarivin combination with IFN- α 2ais effective for treating MERS-CoV infection [16]. Also, the prophylactic and therapeutic interventions include monoclonal human antibodies targeting [27-29]. Moreover interferon treatment in vitro is a proposed treatment, including the encoding of elements for a greater number of genes allowing open-boundary evasions to the host's immune system, until high titers are established [30].

Also, virus shedding, viral loads in lung tissues, hosts' gene expression with regulation, cytokines production and were observed during MERS-CoV infection [31]. Moreover another study examined that detectable antibodies found in the dead patients, the co-detection of antibodies with viral RNA can be utilized for developing therapeutics and vaccines [32]. Also, the role of IFN-I was examined, and demonstrated for clearing the virus and sustaining the survival of host during the infection - the study identified that virus replication and IFN-I response are critical aspects to identify the treatment and therapy for acute viral infections [33].

In conclusion, the current pandemic urges the important concern for realizing the pathogen capability for establishing and inducing infection in human with accordant clinical manifestations [34]. The natural response of the immune system for MERS-CoV and SARS-CoV evasion and lung pathology development according to viral attack are significant aspects to analyze the pathogenesis investigation of SARS-CoV-2 in humans. Since the laboratory features, radiology tests, and demogprahic characterstics of SARS-CoV-2 is similar to other coronaviruses [4], therefore (RT-PCR) can be considered an efficient technique for estimating the rate of fatality by SARS-CoV-2 infection - moreover improving intensive care unit (ICU) services, timely monitoring for virus-specific antibodies neutralization, avoidance for complications are successful measures for recovery until an antiviral treatment is not proposed [35]. Other than this, IFN- α 2a or IFN- α combination with ribarivin, the role of IFN-I, and avoiding the deficiency of IFN- β 1a are appropriate approaches can be tested against SARS- CoV-2 treatment [16, 23, 33].

Acknowledgements

Conflict of Interest

The authors declare no conflict of information for this research.

References

References

1. Kim Jeong-Min, Chung Yoon-Seok, Jo Hye Jun, Lee Nam-Joo, Kim Mi Seon, Woo Sang Hee, Park Sehee, Kim Jee Woong, Kim Heui Man, Han Myung-Guk. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. *Osong Public Health and Research Perspectives*. 2020; 11(1)[DOI](#)
2. Chan Jasper Fuk-Woo, To Kelvin Kai-Wang, Tse Herman, Jin Dong-Yan, Yuen Kwok-Yung. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. *Trends in Microbiology*. 2013; 21(10)[DOI](#)
3. Perlman Stanley, Netland Jason. Coronaviruses post-SARS: update on replication and pathogenesis. *Nature Reviews. Microbiology*. 2009; 7(6)[DOI](#)

4. Petrosillo N., Viceconte G., Ergonul O., Ippolito G., Petersen E.. COVID-19, SARS and MERS: are they closely related?. *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020; 26(6)[DOI](#)
5. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) [Internet]. Who.int. 2019 [cited 2020 May 30]. Available from: [https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-\(mers-cov\)](https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov)).
6. Zumla Alimuddin, Hui David S., Perlman Stanley. Middle East respiratory syndrome. *Lancet (London, England)*. 2015; 386(9997)[DOI](#)
7. Meyer Benjamin, Müller Marcel A., Corman Victor M., Reusken Chantal B. E. M., Ritz Daniel, Godeke Gert-Jan, Lattwein Erik, Kallies Stephan, Siemens Artem, Beek Janko, Drexler Jan F., Muth Doreen, Bosch Berend-Jan, Wernery Ulrich, Koopmans Marion P. G., Wernery Renate, Drosten Christian. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. *Emerging Infectious Diseases*. 2014; 20(4)[DOI](#)
8. Oboho Ikwo K., Tomczyk Sara M., Al-Asmari Ahmad M., Banjar Ayman A., Al-Mugti Hani, Aloraini Muhannad S., Alkhalidi Khulud Z., Almohammadi Emad L., Alraddadi Basem M., Gerber Susan I., Swerdlow David L., Watson John T., Madani Tariq A.. 2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. *The New England Journal of Medicine*. 2015; 372(9)[DOI](#)
9. Assiri Abdullah, McGeer Allison, Perl Trish M., Price Connie S., Al Rabeeah Abdullah A., Cummings Derek A. T., Alabdullatif Zaki N., Assad Maher, Almulhim Abdulmohsen, Makhdoom Hatem, Madani Hossam, Alhakeem Rafat, Al-Tawfiq Jaffar A., Cotten Matthew, Watson Simon J., Kellam Paul, Zumla Alimuddin I., Memish Ziad A.. Hospital outbreak of Middle East respiratory syndrome coronavirus. *The New England Journal of Medicine*. 2013; 369(5)[DOI](#)
10. Memish Ziad A., Zumla Alimuddin I., Al-Hakeem Rafat F., Al-Rabeeah Abdullah A., Stephens Gwen M.. Family cluster of Middle East respiratory syndrome coronavirus infections. *The New England Journal of Medicine*. 2013; 368(26)[DOI](#)
11. Hui David S., Azhar Esam I., Kim Yae-Jean, Memish Ziad A., Oh Myoung-Don, Zumla Alimuddin. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. *The Lancet. Infectious Diseases*. 2018; 18(8)[DOI](#)
12. Drosten Christian, Meyer Benjamin, Müller Marcel A., Corman Victor M., Al-Masri Malak, Hossain Raheela, Madani Hosam, Sieberg Andrea, Bosch Berend Jan, Lattwein Erik, Alhakeem Raafat F., Assiri Abdullah M., Hajomar Waleed, Albarrak Ali M., Al-Tawfiq Jaffar A., Zumla Alimuddin I., Memish Ziad A.. Transmission of MERS-coronavirus in household contacts. *The New England Journal of Medicine*. 2014; 371(9)[DOI](#)
13. Alfaraj Sarah H., Al-Tawfiq Jaffar A., Altuwaijri Talal A., Memish Ziad A.. Middle East Respiratory Syndrome Coronavirus and Pulmonary Tuberculosis Coinfection: Implications for Infection Control. *Intervirology*. 2017; 60(1-2)[DOI](#)
14. Saad Mustafa, Omrani Ali S., Baig Kamran, Bahloul Abdelkarim, Elzein Fatehi, Matin Mohammad Abdul, Selim Mohei A. A., Al Mutairi Mohammed, Al Nakhli Daifullah, Al Aidaroos Amal Y., Al Sherbeeni Nisreen, Al-Khashan Hesham I., Memish Ziad A., Albarrak Ali M.. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*. 2014; 29[DOI](#)
15. Al-Gethamy Manal, Corman Victor M., Hussain Raheela, Al-Tawfiq Jaffar A., Drosten Christian, Memish Ziad A.. A case of long-term excretion and subclinical infection with Middle East respiratory syndrome coronavirus in a healthcare worker. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2015; 60(6)[DOI](#)
16. Shalhoub Sarah, Farahat Fayssal, Al-Jiffri Abdullah, Simhairi Raed, Shamma Omar, Siddiqi Nauman, Mushtaq Adnan. IFN- α 2a or IFN- β 1a in combination with ribavirin to treat Middle

- East respiratory syndrome coronavirus pneumonia: a retrospective study. *The Journal of Antimicrobial Chemotherapy*. 2015; 70(7)[DOI](#)
17. Banik Gouri Rani, Alqahtani Amani Salem, Booy Robert, Rashid Harunor. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. *Virologica Sinica*. 2016; 31(1)[DOI](#)
 18. Badawi Alaa, Ryou Seung Gwan. Prevalence of Diabetes in the 2009 Influenza A (H1N1) and the Middle East Respiratory Syndrome Coronavirus: A Systematic Review and Meta-Analysis. *Journal of Public Health Research*. 2016; 5(3)[DOI](#)
 19. International Diabetes Federation. IDF DIABETES ATLAS [Internet]. Diabetesatlas.org. 2019 [cited 2020 May 30]. Available from: https://diabetesatlas.org/upload/resources/2019/2019_regional_factsheet.pdf.
 20. Sabir Jamal S. M., Lam Tommy T.-Y., Ahmed Mohamed M. M., Li Lifeng, Shen Yongyi, Abo-Aba Salah E. M., Qureshi Muhammd I., Abu-Zeid Mohamed, Zhang Yu, Khiyami Mohammad A., Alharbi Njud S., Hajrah Nahid H., Sabir Meshaal J., Mutwakil Mohammed H. Z., Kabli Saleh A., Alsulaimany Faten A. S., Obaid Abdullah Y., Zhou Boping, Smith David K., Holmes Edward C., Zhu Huachen, Guan Yi. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. *Science (New York, N.Y.)*. 2016; 351(6268)[DOI](#)
 21. WHO. Diabetes country profile, Saudi Arabia [Internet]. 2017. Available from: https://www.who.int/diabetes/country-profiles/sau_en.pdf.
 22. Choi Won Suk, Kang Cheol-In, Kim Yonjae, Choi Jae-Phil, Joh Joon Sung, Shin Hyoung-Shik, Kim Gayeon, Peck Kyong Ran, Chung Doo Ryeon, Kim Hye Ok, Song Sook Hee, Kim Yang Ree, Sohn Kyung Mok, Jung Younghee, Bang Ji Hwan, Kim Nam Joong, Lee Kkot Sil, Jeong Hye Won, Rhee Ji-Young, Kim Eu Suk, Woo Heungjeong, Oh Won Sup, Huh Kyungmin, Lee Young Hyun, Song Joon Young, Lee Jacob, Lee Chang-Seop, Kim Baek-Nam, Choi Young Hwa, Jeong Su Jin, Lee Jin-Soo, Yoon Ji Hyun, Wi Yu Mi, Joung Mi Kyong, Park Seong Yeon, Lee Sun Hee, Jung Sook-In, Kim Shin-Woo, Lee Jae Hoon, Lee Hyuck, Ki Hyun Kyun, Kim Yeon-Sook. Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea. *Infection & Chemotherapy*. 2016; 48(2)[DOI](#)
 23. Kim Eu Suk, Choe Pyoeng Gyun, Park Wan Beom, Oh Hong Sang, Kim Eun Jung, Nam Eun Young, Na Sun Hee, Kim Moonsuk, Song Kyoung-Ho, Bang Ji Hwan, Park Sang Won, Kim Hong Bin, Kim Nam Joong, Oh Myoung-don. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. *Journal of Korean Medical Science*. 2016; 31(11)[DOI](#)
 24. Kim K. H., Tandi T. E., Choi J. W., Moon J. M., Kim M. S.. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. *The Journal of Hospital Infection*. 2017; 95(2)[DOI](#)
 25. Oh Myoung-don, Park Wan Beom, Park Sang-Won, Choe Pyoeng Gyun, Bang Ji Hwan, Song Kyoung-Ho, Kim Eu Suk, Kim Hong Bin, Kim Nam Joong. Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. *The Korean Journal of Internal Medicine*. 2018; 33(2)[DOI](#)
 26. Omrani Ali S., Saad Mustafa M., Baig Kamran, Bahloul Abdelkarim, Abdul-Matin Mohammed, Alaidaroos Amal Y., Almakhlafi Ghaleb A., Albarrak Mohammed M., Memish Ziad A., Albarrak Ali M.. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. *The Lancet. Infectious Diseases*. 2014; 14(11)[DOI](#)
 27. Jiang Liwei, Wang Nianshuang, Zuo Teng, Shi Xuanling, Poon Kwok-Man Vincent, Wu Yongkang, Gao Fei, Li Danyang, Wang Ruoke, Guo Jianying, Fu Lili, Yuen Kwok-Yung, Zheng Bo-Jian, Wang Xinquan, Zhang Linqi. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. *Science Translational Medicine*. 2014; 6(234)[DOI](#)
 28. Lu Lu, Liu Qi, Zhu Yun, Chan Kwok-Hung, Qin Lili, Li Yuan, Wang Qian, Chan Jasper Fuk-Woo, Du Lanying, Yu Fei, Ma Cuiqing, Ye Sheng, Yuen Kwok-Yung, Zhang Rongguang, Jiang Shibo. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. *Nature Communications*. 2014; 5[DOI](#)

29. Tang Xian-Chun, Agnihothram Sudhakar S., Jiao Yongjun, Stanhope Jeremy, Graham Rachel L., Peterson Eric C., Avnir Yuval, Tallarico Aimee St Clair, Sheehan Jared, Zhu Quan, Baric Ralph S., Marasco Wayne A.. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. *Proceedings of the National Academy of Sciences*. 2014; 111(19)[DOI](#)
30. Gralinski Lisa E, Baric Ralph S. Molecular pathology of emerging coronavirus infections. *The Journal of Pathology*. 2015; 235(2)[DOI](#)
31. Wit Emmie, Rasmussen Angela L., Falzarano Darryl, Bushmaker Trenton, Feldmann Friederike, Brining Douglas L., Fischer Elizabeth R., Martellaro Cynthia, Okumura Atsushi, Chang Jean, Scott Dana, Benecke Arndt G., Katze Michael G., Feldmann Heinz, Munster Vincent J.. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. *Proceedings of the National Academy of Sciences*. 2013; 110(41)[DOI](#)
32. Al-Abdely Hail M., Midgley Claire M., Alkhamis Abdulrahim M., Abedi Glen R., Lu Xiaoyan, Binder Alison M., Alanazi Khalid H., Tamin Azaibi, Banjar Weam M., Lester Sandra, Abdalla Osman, Dahl Rebecca M., Mohammed Mutaz, Trivedi Suvang, Algarni Homoud S., Sakthivel Senthilkumar K., Algwizani Abdullah, Bafaqeeh Fahad, Alzahrani Abdullah, Alsharef Ali Abraheem, Alhakeem Raafat F., Jokhdar Hani A. Aziz, Ghazal Sameeh S., Thornburg Natalie J., Erdman Dean D., Assiri Abdullah M., Watson John T., Gerber Susan I.. Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia. *Emerging Infectious Diseases*. 2019; 25(4)[DOI](#)
33. Channappanavar Rudragouda, Fehr Anthony R., Zheng Jian, Wohlford-Lenane Christine, Abrahante Juan E., Mack Matthias, Sompallae Ramakrishna, McCray Paul B., Meyerholz David K., Perlman Stanley. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. *The Journal of Clinical Investigation*. 129(9)[DOI](#)
34. Kolifarhood G, Aghaali M, Mozafar Saadati H, Taherpour N, Rahimi S, Izadi N, et al. Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. *Arch Acad Emerg Med*. 2020 Apr 1;8(1).. 2020; 18(1)
35. Public Health England. Treatment of MERS-CoV: Information for Clinicians Clinical decision-making support for treatment of MERS-CoV patients [Internet]. PHE Publications; 2017. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/638628/MERS_CoV_guidance_for_clinicians.pdf.